Moderna Stock (NASDAQ: MRNA) is a publicly traded biotechnology company that produces a line of therapeutic vaccines aimed at combating viral infections. Its stock price is up by more than 15% this year, due in part to the success of the Moderna Vaccine line of therapeutic vaccines. This growth is due in part to the recent announcement that the company’s clinical trial for its third line of therapeutic vaccines has shown early results. As such, this article is about the recent positive Moderna Stock Price movement and how investors can capitalize on it.
The recent announcement of the positive results of the company’s third line of therapeutic vaccines has been met with mixed reviews from both sides of the debate. Some people believe that these results indicate that there is a strong likelihood that Moderna’s therapeutic vaccines will work. Others feel that the positive results are not necessarily indicative of the efficacy of the drugs and question whether or not the company is really prepared to take the chance on further clinical testing. In this article I will outline some of the reasons why investors should buy Moderna Stock if you want to get in on the ground floor of the new therapeutic vaccines market.
The first reason that investors should buy Moderna Stock now if you want to get in on the ground floor of the new therapeutic vaccines market is because its current clinical trial for a new anti-viral called “Zyprexa” appears to be quite positive. Zyprexa is a widely prescribed drug to control the appetite for food. Moderna’s “Zyprexa Anti-Appetite Therapy” clinical trial indicates that the drug appears to have some promise for reducing weight gain during the early stages of treatment.
This is also a major positive reaction to the news that one of the three drugs being tested in this trial appears to be more effective than the other two. However, the negative side effects associated with the drug have many people worried. Thus, this may cause investors to stay far away from this drug and hope that other companies develop a more effective antiviral for controlling weight.
The second reason that you should buy Moderna Stock right now if you are an investor is the fact that it has already been approved by the FDA for the treatment of certain types of genital warts. These types of warts are caused by an HPV virus and they are very difficult to treat. The reason that this is important for investors to know is because many of the anti-viral drugs for treating genital warts have been around for over a decade and have very limited success rates. For example, Herpes Zeta virus based drugs have had some very poor success rates and their use was eventually abandoned because they were not being able to effectively treat the genital warts. This makes it very unlikely that the new anti-viral drug “Zyprexa” will have any better success.
With all of that said, investors are hopeful that this new clinical trial for “Zyprexa” will prove itself as effective as its other competitors in its class. The news of a positive Moderna Stock Price reflects the fact that the company has already received FDA approval for the treatment of genital warts and is likely to receive more positive results in its studies. Therefore, this means that more people will benefit from the drug than its competition as a result of the positive Moderna Stock Price reaction.